Stock analysts at Truist Financial assumed coverage on shares of NewAmsterdam Pharma (NASDAQ:NAMS – Get Free Report) in a note issued to investors on Wednesday. The brokerage set a “buy” rating and a $57.00 price target on the stock. Truist Financial’s price objective points to a potential upside of 93.61% from the stock’s previous close. […]

Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has been given an average recommendation of “Hold” by the thirteen research firms that are covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and three have given a buy recommendation to the […]